MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。动脉粥样硬化多民族研究（MESA）是一项为期10年的由nhlbi资助的亚临床心血管疾病（在产生体征和症状之前无创检测到的疾病）的多中心研究。本研究的总体目标是确定亚临床动脉粥样硬化患者的特征，预测临床心脏病事件的进展。本研究的具体目的是：确定与临床心脏病相关的特征；确定亚临床疾病的新指标；并开发识别无症状高危人群的方法，用于未来的筛查和干预研究。我们将通过作为现场中心参与一项协作、多中心、队列研究来实现这些目标，研究对象为年龄在45-84岁之间、基线时无临床心血管疾病证据的人群。在研究的前18个月，我们目前正在参与合作协议的制定和试点研究阶段。从2000年夏天开始，我们将在WFUSM现场中心招募1100名福赛斯县的成年人（其中50%是非裔美国人）。参与者将使用一些技术程序评估亚临床心血管疾病。这些数据对于更好地设计未来的临床和基于人群的干预方案以进一步减少美国心血管疾病的负担将是重要的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Multi-Ethnic Study of Atherosclerosis (MESA) is a 10-year NHLBI-funded multi-center study of subclinical cardiovascular disease (disease detected non-invasively before it has produced signs and symptoms). The overall goal of this study is to identify characteristics of persons with subclinical atherosclerosis that predict progression to clinical heart disease events. The specific aims of this study are: to determine characteristics related to clinical heart disease; to identify new measures of subclinical disease; and to develop methods for identifying the highest risk asymptomatic persons for application in future screening and intervention studies. We will accomplish these aims by participating as a field center in a collaborative, multi-center, cohort study of persons ages 45-84 years without evidence of clinical cardiovascular disease at baseline. We are currently participating in the collaborative protocol development and the pilot study phase, during the first 18 months of the study. We will begin recruiting 1,100 Forsyth County adults at the WFUSM field center (including 50% African Americans) beginning in the Summer of 2000. Participants will be evaluated for subclinical cardiovascular disease using a number of technologic procedures. These data will be important to better design future clinical and population-based intervention programs to further reduce the burden of cardiovascular disease in the United States.